Durability of SVR in chronic hepatitis C patients treated with peginterferon-2a/ribavirin in combination with a direct-acting anti-viral

被引：27

作者：

Rutter, K. ^{[1
]}

Hofer, H. ^{[1
]}

Beinhardt, S. ^{[1
]}

Dulic, M. ^{[2
]}

Gschwantler, M. ^{[2
]}

Maieron, A. ^{[3
]}

Laferl, H. ^{[4
]}

Staettermayer, A. F. ^{[1
]}

Scherzer, T. -M. ^{[1
]}

Strassl, R. ^{[5
]}

Holzmann, H. ^{[5
]}

Steindl-Munda, P. ^{[1
]}

Ferenci, P. ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria

[2] Wilhelminenspital Stadt Wien, Dept Internal Med 4, Vienna, Austria

[3] Hosp Elisabethinen, Linz, Austria

[4] Kaiser Franz Josef Spital, Dept Internal Med, Vienna, Austria

[5] Med Univ Vienna, Dept Clin Virol, A-1090 Vienna, Austria

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2013年 / 38卷 / 02期

关键词：

SUSTAINED VIROLOGICAL RESPONSE; TREATMENT-NAIVE PATIENTS; TERM-FOLLOW-UP; HISTOLOGIC IMPROVEMENT; INTERFERON-ALPHA; RIBAVIRIN; TELAPREVIR; GENOTYPE; MORTALITY; FIBROSIS;

D O I：

10.1111/apt.12350

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background The introduction of direct-acting anti-virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long-term durability of viral eradication after successful triple therapy are lacking. Aim To evaluate the long-term durability of viral eradication in patients treated with triple therapy, including direct-acting anti-virals. Methods Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon-2a/ribavirin in combination with a direct-acting anti-viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR. The median follow-up after the patients was 21 (range: 7-64) months. Results One hundred and three patients with chronic hepatitis C genotype 1 infection [f/m: 34/69; GT-1b: 67 GT-1a: 34, GT-4: 2; mean age: 47.6years (45.5-49.7; 95% CI)] achieving a SVR triple therapy were followed. Two cases of late relapses (2/103, 1.9%; 95% CI: 0.24-6.8) were observed. One patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment. The relapses occurred 8 and 12months after cessation of anti-viral treatment. Cloning sequencing revealed identical sequence in both patients. Resistance analysis revealed no presence of viral resistance. Conclusion Like the SVR after peginterferon-2/ribavirin combination treatment, HCV eradication after triple therapy remains durable after long-term follow-up.

引用

页码：118 / 123

页数：6

共 29 条

[1] Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy [J].

Bonkovsky, HL ;

Woolley, JM .

HEPATOLOGY, 1999, 29 (01) :264-270

[2] Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis:: A retrospective study [J].

Bruno, Savino ;

Stroffolini, Tommaso ;

Colombo, Massimo ;

Bollani, Simona ;

Benvegnu, Luisa ;

Mazzella, Giuseppe ;

Ascione, Antonio ;

Santantonio, Teresa ;

Piccinino, Felice ;

Andreone, Pietro ;

Mangia, Alessandra ;

Gaeta, Giovanni B. ;

Persico, Marcello ;

Fagiuoli, Stefano ;

Almasio, Piero L. .

HEPATOLOGY, 2007, 45 (03) :579-587

[3] A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis [J].

D'Ambrosio, Roberta ;

Aghemo, Alessio ;

Rumi, Maria Grazia ;

Ronchi, Guido ;

Donato, Maria Francesca ;

Paradis, Valerie ;

Colombo, Massimo ;

Bedossa, Pierre .

HEPATOLOGY, 2012, 56 (02) :532-543

[4] Prevalence and Follow-Up of Occult HCV Infection in an Italian Population Free of Clinically Detectable Infectious Liver Disease [J].

De Marco, Laura ;

Manzini, Paola ;

Trevisan, Morena ;

Gillio-Tos, Anna ;

Danielle, Franca ;

Balloco, Cinzia ;

Pizzi, Alessandra ;

De Filippo, Eleonora ;

D'Antico, Sergio ;

Violante, Beatrice ;

Valfre, Adriano ;

Curti, Franco ;

Merletti, Franco ;

Richiardi, Lorenzo .

PLOS ONE, 2012, 7 (08)

[5] FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL [J].

Ferenci, P. ;

Asselah, T. ;

Foster, G. R. ;

Zeuzem, S. ;

Sarrazin, C. ;

Moreno, C. ;

Ouzan, D. ;

Maevskaya, M. ;

Calinas, F. ;

Morano, L. E. ;

Crespo, J. ;

Dufour, J. -F. ;

Bourliere, M. ;

Agarwal, K. ;

Forton, D. ;

Schuchmann, M. ;

Zehnter, E. ;

Nishiguchi, S. ;

Omata, M. ;

Stern, J. O. ;

Datzenko, Y. ;

Scherer, J. ;

Quinson, A. -M. .

JOURNAL OF HEPATOLOGY, 2013, 58 :S569-S570

[6] Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy [J].

Formann, E ;

Steindl-Munda, P ;

Hofer, H ;

Jessner, W ;

Bergholz, U ;

Gurguta, C ;

Ferenci, P .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (04) :507-511

[7] Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection [J].

Hezode, Christophe ;

Forestier, Nicole ;

Dusheiko, Geoffrey ;

Ferenci, Peter ;

Pol, Stanislas ;

Goeser, Tobias ;

Bronowicki, Jean-Pierre ;

Bourliere, Marc ;

Gharakhanian, Shahin ;

Bengtsson, Leif ;

McNair, Lindsay ;

George, Shelley ;

Kieffer, Tara ;

Kwong, Ann ;

Kauffman, Robert S. ;

Alam, John ;

Pawlotsky, Jean-Michel ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (18) :1839-1850

[8]

Innes HA, 2011, HEPATOLOGY, V54, P2281, DOI [10.1002/hep.24561, 10.1002/hep.24776]

[9] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[10] A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS [J].

Lawitz, E. ;

Poordad, F. ;

Kowdley, K. V. ;

Jensen, D. ;

Cohen, D. E. ;

Siggelkow, S. ;

Wikstrom, K. ;

Larsen, L. ;

Menon, R. M. ;

Podsadecki, T. ;

Bernstein, B. .

JOURNAL OF HEPATOLOGY, 2012, 56 :S7-S7

← 1 2 3 →